Skip to main content

Advertisement

Table 3 Multivariable Cox analysis for composite endpoints

From: Prognostic impact of HbA1c variability on long-term outcomes in patients with heart failure and type 2 diabetes mellitus

  HR (model 3) 95% confidence interval P value HR (model 4) 95% confidence interval P value
HbA1c-SD (high, low) 1.485 1.251–1.763 < 0.001
HbA1c-CV (high, low) 1.378 1.160–1.638 < 0.001
E/e′ 1.045 1.008–1.084 0.018 1.040 01.003–1.079 0.034
LVEF (≥ 50, 40–49, < 40%) 1.093 0.989–1.208 0.081 1.106 1.001–1.222 0.048
age 1.011 0.999–1.022 0.069 1.010 0.999–1.022 0.073
eGFR 0.995 0.985–1.004 0.262 0.994 0.984–1.003 0.184
Beta-blocker 0.810 0.668–0.982 0.032 0.794 0.655–0.964 0.020
ACEI/ARB 1.029 0.827–1.280 0.799 1.018 0.818–1.266 0.873
BNP (tertile) 1.149 1.035–1.276 0.009 1.136 1.017–1.261 0.017
Ischemic HF 1.097 0.925–1.300 0.288 1.095 0.924–1.298 0.296
NYHA 1.075 0.963–1.201 0.199 1.085 0.971–1.212 0.148
Gender 0.916 0.760–1.103 0.354 0.921 0.764–1.109 0.386
Baseline HbA1c 0.994 0.862–1.146 0.933 0.987 0.856–1.137 0.854
Number of HbA1c measurements 1.010 0.968–1.154 0.646 1.007 0.965–1.051 0.739
HbA1c–mean 0.992 0.864–1.140 0.911 1.066 0.926–1.227 0.372
  1. HbA1c hemoglobin A1c, HbA1c-SD standard deviation of HbA1c, HbA1c-CV coefficient of variation of HbA1c, E/e′ mitral Doppler early velocity/mitral annular early velocity, LVEF left ventricular ejection fraction, eGFR estimated glomerular filtration rate, ACEI/ARB angiotensin converting enzyme inhibitor/angiotensin II receptor blocker, BNP B-type natriuretic peptides, MI myocardial infarction, NYHA New York Heart Association functional class